COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

11.90 -0.05 (-0.42%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

33 34 Next >

EXCLUSIVE: Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo, Market Subverticals & Informal Guidance ↗

November 07, 2022

(Part four of a four-part series) See previous stories in this series:

Via Benzinga

COMPASS Pathways Shares Q3 2022 Financial Results, Business News & Term's Highlights ↗

November 04, 2022

Psychedelics mental healthcare firm COMPASS Pathways (NASDAQ: CMPS) reported its financial outcomes for the third quarter ended 30 September 2022 and gave an update on its most recent pipeline and...

Via Benzinga

Psychedelic Stock Gainers And Losers From November 3, 2022 ↗

November 03, 2022

GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 4.80% at $10.27

Via Benzinga

COMPASS Pathways plc (CMPS) Q3 2022 Earnings Call Transcript ↗

November 03, 2022

CMPS earnings call for the period ending September 30, 2022.

Via The Motley Fool

Psyched Wellness is The First Public Company To Bring Amanita Muscaria For Human Consumption To The U.S. ↗

November 03, 2022

Easily identified by its red cap covered with white dots and a white stem, the Amanita muscaria mushroom is probably the most famous and easily recognizable mushroom in the world. Popularized by Lewis...

Via Benzinga

Compass Pathways: Q3 Earnings Insights ↗

November 03, 2022

Compass Pathways (NASDAQ:CMPS) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights

November 03, 2022

From COMPASS Pathways

Via GlobeNewswire

Compass Pathways, Small Pharma Among Top Psychedelic Movers Of Today ↗

November 02, 2022

GAINERS: GH Research (NASDAQ:GHRS) shares closed up 3.90% at $10.39 LOSERS:

Via Benzinga

Compass Pathways's Earnings Outlook ↗

November 02, 2022

Compass Pathways (NASDAQ:CMPS) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Compass...

Via Benzinga

Why Shares of atai Life Sciences Climbed 14.58% on Tuesday ↗

November 01, 2022

The company specializes in developing psychedelics as therapies.

Via The Motley Fool

EXCLUSIVE: Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo's Investment Fundamentals & Specificities ↗

October 31, 2022

(Part one of a four-part series)

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗

November 01, 2022

Upgrades

Via Benzinga

15 Global Psychedelics Executives To Keep An Eye On In 2022 ↗

October 28, 2022

As the global psychedelics industry booms, with companies going public, major financings being announced, and celebrities and big investors getting on board, Benzinga has decided to put together a list...

Via Benzinga

October Recap: Major Psychedelic Drug Stocks Declined 9.9% ↗

October 27, 2022

In total, thePsychedelic Drug Stock Index went down 9.9% in September and is now down 64.7% YTD.

Via Talk Markets

Revive Therapeutics, Small Pharma Among Top Psychedelic Movers Of Today ↗

October 27, 2022

GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 3.00% at $0.87

Via Benzinga

Psychedelic Stock Gainers And Losers From October 26, 2022 ↗

October 26, 2022

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 5.39% at $0.18

Via Benzinga

Psychedelic Stock Gainers And Losers From October 25, 2022 ↗

October 25, 2022

GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 6.24% at $10.39

Via Benzinga

Cannabis Category Performances Ranged From +14.4% To -4.6% This Past Week ↗

October 24, 2022

The 5 categories in the cannabis sector perform quite differently week to week. Below is a summary of how each category performed last week, in descending order and since the end of September and since...

Via Talk Markets

Major Psychedelic Stock Downward Trend Continues ↗

October 24, 2022

The 8 constituents of our Psychedelic Drug Stocks Index continue to collectively show poor performance, down 4.6% more last week and now down 45.5% since the end of August.

Via Talk Markets

Allied, Small Pharma Among Top Psychedelic Movers Of Today ↗

October 21, 2022

GAINERS: Allied (OTC:ALID) shares closed up 10.21% at $0.53

Via Benzinga

Psychedelic Stock Gainers And Losers From October 18, 2022 ↗

October 18, 2022

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 15.76% at $0.14

Via Benzinga

Psychedelic Stock Gainers And Losers From October 17, 2022 ↗

October 17, 2022

GAINERS: Biomind Labs (OTC:BMNDF) shares closed up 38.18% at $1.52

Via Benzinga

Psyched: VC Fund Invests $50M In Psychedelics, Musk's 'Exploratory Journeys', Native American Use Of Peyote And More ↗

October 14, 2022

Palo Santo Closes $50M Investment Fund Palo Santo, a venture capital fund focused on backing and building emerging psychedelic therapeutics companies, recently announced the closing of its $50 million...

Via Benzinga

Small Pharma, Cybin Among Top Psychedelic Movers Of Today ↗

October 14, 2022

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 9.12% at $0.12

Via Benzinga

Psychedelic Stock Gainers And Losers From October 12, 2022 ↗

October 12, 2022

GAINERS: Allied (OTC:ALID) shares closed up 48.05% at $0.48

Via Benzinga

Compass Pathways Will Lead Two Concurrent Phase 3 Trials On Psilocybin-Assisted Therapy For Depression ↗

October 12, 2022

Psychedelics biotech company Compass Pathways (NASDAQ: CMPS) announced it will conduct two separate Phase 3 clinical trials to study psilocybin-assisted therapy on Treatment-Resistant Depression...

Via Benzinga

Numinus Wellness, Small Pharma Among Top Psychedelic Movers Of Today ↗

October 11, 2022

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 7.61% at $0.12

Via Benzinga

Psychedelic Drugs Prove Their Worth In Clinical Trials

October 11, 2022

Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial...

Via PressReach

Psychedelic Stock Gainers And Losers From October 10, 2022 ↗

October 10, 2022

GAINERS: Cybin (AMEX:CYBN) shares closed up 5.51% at $0.63 LOSERS:

Via Benzinga

Psychedelic Drug Stocks Index Up Slightly This Week ↗

October 08, 2022

There are 8 stocks in the munKNEE Psychedelic Drug Stocks Index and this article reveals how its constituents performed this week, in descending order, since the end of August and YTD.

Via Talk Markets

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.